The Central Nervous System Effects of Two Different HIV-Integrase Inhibitor Containing Antiretroviral Regimens.

Trial Profile

The Central Nervous System Effects of Two Different HIV-Integrase Inhibitor Containing Antiretroviral Regimens.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2016

At a glance

  • Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 10 Dec 2015 Accrual to date is 45% according to United Kingdom Clinical Research Network record.
    • 05 Nov 2015 Accrual to date is 36% according to United Kingdom Clinical Research Network record.
    • 07 Oct 2015 Accrual to date is 31% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top